Results 141 to 150 of about 84,576 (334)

Beyond BMI: Practical Guide for Clinicians to Integrate the Lancet Commission's Obesity Framework and King's Obesity Staging System

Clinical Obesity, EarlyView.
ABSTRACT Body mass index (BMI) on its own is a poor diagnostic and staging tool for obesity because it does not measure health status. The newly published Lancet Clinical Obesity Criteria (LCOC) for defining clinical obesity distinguish preclinical and clinical obesity based on organ or tissue dysfunction.
Tak Ying Louise Ko, Alexander D. Miras, Dimitri J. Pournaras, Carel W. Le Roux   +3 more
wiley   +1 more source

Chronic thromboembolic pulmonary hypertension after the first episode of pulmonary embolism? How often?

Biomedical Papers, 2016
Background: Surviving pulmonary embolism (PE) brings a risk of thromboembolic disease chronicity. Chronic thromboembolic pulmonary hypertension (CTEPH) develops as a result of one or multiple pulmonary embolic events.
Zdenek Vavera, Jan Vojacek, Radek Pudil, Jaroslav Maly, Pavel Elias   +4 more
doaj   +1 more source

The impact of peripheral arterial disease on patients with mechanical circulatory support. [PDF]

, 2020
Background: Left ventricular assist devices (LVAD) are indicated as bridging or destination therapy for patients with advanced (Stage D) heart failure and reduced ejection fraction (HFrEF). Due to the clustering of the mutual risk factors, HFrEF patients
Ajmal, Rasikh, Al-Khadra, Yasser, Alraies, M Chadi, Asfour, Abedelrahim, Darmoch, Fahed, Gardi, Delair, Glazier, James, Mir, Tanveer, Moussa-Pacha, Homam, Sattar, Yasar, Ullah, Waqas   +10 more
core   +1 more source

Relation of the stress hyperglycaemia ratio to residual risk in anticoagulated patients with atrial fibrillation: A report from the prospective Murcia AF Project III cohort

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Introduction Atrial fibrillation (AF) carries residual thromboembolic and cardiovascular risk despite oral anticoagulation (OAC). The stress hyperglycaemia ratio (SHR), derived from admission glucose and glycated haemoglobin (HbA1c), integrates information on both acute glycaemic fluctuations and chronic glycaemic burden.
Eva Soler‐Espejo, Yang Chen, José Miguel Rivera‐Caravaca, José Antonio Sánchez‐Salas, María Asunción Esteve‐Pastor, Francisco Marín, Vanessa Roldán, Gregory Y. H. Lip   +7 more
wiley   +1 more source

The trajectory to diagnosis with pulmonary arterial hypertension: a qualitative study [PDF]

, 2012
Objectives To investigate the patient's experience of the trajectory to receiving a diagnosis of pulmonary arterial hypertension (PAH) and inform the provision of care for this patient group.
Armstrong, I, Bundock, S, Harries, C, Rochnia, NK, Yorke, J   +4 more
core   +2 more sources

Effectiveness of direct oral anticoagulants for all‐cause mortality and cardiovascular events in overweight and obese patients with atrial fibrillation: Insight from the nationwide START registry

European Journal of Clinical Investigation, EarlyView.
This study shows that overweight and obese patients with atrial fibrillation experience improved outcomes when treated with DOACs compared with VKAs. Specifically, DOAC use was associated with lower risks of all‐cause mortality and cardiovascular events.
Danilo Menichelli, Gianluca Gazzaniga, Emilia Antonucci, Gualtiero Palareti, Daniela Poli, Pasquale Pignatelli, Daniele Pastori, the START2 Register Investigators, Benilde Cosmi, Daniela Poli, Elena Lotti, Martina Berteotti, Walter Ageno, Giovanna Colombo, Salvatore Bradamante, Eugenio Bucherini, Monica Vastola, Paola Casasco, Antonio Chistolini, Alessandra Serrao, Luciano Crippa Ambulatorio Emostasi, Raimondo De Cristofaro, Erica De Candia, Valeria De Micheli, Marcello Di Nisio, Anna Falanga, Teresa Lerede, Elvira Grandone, Donatella Colaizzo, Antonio Insana, Nicola Lucio Liberato, Domenico Lione, Rosa Maria Lombardi, Giacomo Lucarelli, Giuseppe Malcangi, Catello Mangione, Giuliana Martini Centro Emostasi, Marco Marzolo, Giovanni Nante, Vincenzo Oriana, Paolo Pedico, Simona Pedrini, Vittorio Pengo, Antonietta Piana, Francesco Cibecchini, Simona Pezzella, Pasquale Pignatelli, Daniele Pastori, Vincenza Rossi, Lucia Ruocco, Paolo Chiarugi, Serena Rupoli, Domizio Serra, Carmine Spataro, Margherita Reduzzi, Sophie Testa, Oriana Paoletti, Vincenzo Toschi, Claudio Vasselli   +58 more
wiley   +1 more source

Cardiovascular Challenges in Chronic Lymphocytic Leukemia (CLL) Patients Undergoing Bruton Tyrosine Kinase (BTK) Inhibitor Therapy

European Journal of Haematology, EarlyView.
ABSTRACT Background/Objectives Bruton tyrosine kinase inhibitors (BTKis) have revolutionized treatment for chronic lymphocytic leukemia (CLL), but cardiovascular (CV) toxicities pose significant challenges. Second‐generation BTKis offer improved target specificity, yet CV risks persist.
Stefano Oliva, Stefano Molica
wiley   +1 more source

CLINICAL CASE: CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION IN A CHILD

Евразийский Кардиологический Журнал, 2017
The article deals with a rare clinical case of chronic thromboembolic pulmonary hypertension in children. This case demonstrates the difficulty of identifying of chronic thromboembolic pulmonary hypertension and masking it under the community-acquired ...
D. J. Sadykova, D. R. Sabirova, I. N. Nurmeev, S. A. Pigalova, N. N. Firsova, N. V. Kustova   +5 more
doaj   +1 more source

Riociguat: Mode of action and clinical development in pulmonary hypertension [PDF]

, 2016
Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) are progressive and debilitating diseases characterized by gradual obstruction of the pulmonary vasculature, leading to elevated pulmonary artery pressure and
Ghofrani, HA, Humbert, M, Klinger, JR, Langleben, D, Schermuly, R, Stasch, JP, Wilkins, MR   +6 more
core   +1 more source

Post‑Marketing Surveillance of the Safety and Effectiveness of Emicizumab in Japanese Patients With Congenital Haemophilia A With Inhibitors

Haemophilia, EarlyView.
ABSTRACT Introduction The bispecific monoclonal antibody emicizumab was approved for prophylactic treatment of congenital haemophilia A (HA) in Japan in 2018. Aim To monitor long‐term safety and effectiveness of emicizumab, including appropriate concomitant use of bypassing agents (BPAs), in Japanese patients with congenital HA with inhibitors who ...
Midori Shima, Katsuyuki Fukutake, Masanori Matsumoto, Yoshihiko Sugimura, Chiaki Sugita, Lyu Ji, Mika Kawano, Tadashi Matsushita   +7 more
wiley   +1 more source